NEW YORK. Pharmaceutical company from the United States (US), Pfizer Inc., invested more than US$ 2.5 billion in Belgian and Irish drug manufacturing plants. Pfizer is preparing to launch a new product that it hopes will make up for lost revenue due to expired patents and slumping sales of its Covid-19 vaccine. One of the world's largest pharmaceutical companies said it plans to spend more than €1.2 billion (US$1.26 billion) to expand its factory in Puurs, Belgium, and invest in the factory. Dublin, Ireland. Pfizer in a press release announced that several investment-related projects are already underway in Belgium. While others are planned to start early in 2023. At the Irish plant, expansion is expected to start in 2024 and be completed in 2027. Efforts To Overcome The Pandemic The Puurs plant plays a key role in the production of the COVID-19 shot developed by Pfizer with German partner BioNTech using messenger RNA (mRNA) technology. Production of the Covid-19 vaccine started at the end of 2020, when Europe and the US began to make efforts to contain the pandemic. Pfizer's revenue is expected to reach US$ 100 billion this year. That estimate more than doubled pre-pandemic due to high sales of the Covid-19 vaccine and Paxlovid treatment.